Skip to main content
SpringerLink
Log in

Vorapaxar: A Review of Its Use in the Long-Term Secondary Prevention of Atherothrombotic Events

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Vorapaxar (Zontivity®) is a first-in-class, potent and orally-active protease-activated receptor 1 (PAR-1) antagonist that blocks thrombin-mediated platelet activation without interfering with thrombin-mediated fibrin deposition. The long-term efficacy of once-daily vorapaxar added to standard antiplatelet therapy (aspirin with or without clopidogrel) in the secondary prevention of atherothrombotic events in patients with a history of myocardial infarction (MI), ischaemic stroke or peripheral arterial disease was investigated in the large, multinational TRA 2°P-TIMI 50 trial. Compared with placebo, vorapaxar significantly reduced the risk of the composite endpoints of cardiovascular (CV) death, MI or stroke, and CV death, MI, stroke or urgent coronary revascularization in the overall trial population. Vorapaxar also significantly reduced the risk of these composite endpoints in the subgroup of patients with prior MI (the largest qualifying disease cohort) and the subset of post-MI patients with no history of stroke or transient ischaemic attack (TIA). Vorapaxar significantly increased the risk of GUSTO moderate and/or severe bleeding in the overall trial population and all key subgroups (including post-MI patients with no history of stroke or TIA). Vorapaxar also significantly increased the risk of intracranial haemorrhage (ICH) in the overall trial population and the subgroup of patients with prior stroke, but not the subgroup of post-MI patients or the subset of post-MI patients with no history of stroke or TIA. Based on these results, vorapaxar has been approved in the EU as an adjunctive treatment for the secondary prevention of atherothrombotic events in patients with prior MI who do not have a history of stroke, TIA or ICH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Leys D. Atherothrombosis: a major health burden. Cerebrovasc Dis. 2001;11(Suppl 2):1–4.

    Article  CAS  PubMed  Google Scholar 

  2. Steg PG, Dorman SH, Amarenco P. Atherothrombosis and the role of antiplatelet therapy. J Thromb Haemost. 2011;9(Suppl 1):325–32.

    Article  CAS  PubMed  Google Scholar 

  3. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular, disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2012;33:1635–701.

    Article  CAS  PubMed  Google Scholar 

  4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–15.

    Article  CAS  PubMed  Google Scholar 

  5. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.

    Article  CAS  PubMed  Google Scholar 

  6. Steg PG, Bhatt DL, Wilson PWF, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197–206.

    Article  CAS  PubMed  Google Scholar 

  7. Domandy JA. Rationale for antiplatelet therapy in patients with atherothrombotic disease. Vasc Med. 1998;3(3):253–5.

    Article  Google Scholar 

  8. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–94.

    Article  CAS  PubMed  Google Scholar 

  9. Leonardi S, Tricoci P, Becker RC. Thrombin receptor antagonists for the treatment of atherosclerosis: therapeutic potential of vorapaxar and E-5555. Drugs. 2010;70(14):1771–83.

    Article  CAS  PubMed  Google Scholar 

  10. Cho JR, Rollini F, Franchi F, et al. Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar. Vasc Health Risk Manag. 2014;10:177–88.

    PubMed Central  PubMed  Google Scholar 

  11. Tello-Montoliu A, Tomasello SD, Ueno M, et al. Antiplatelet therapy: thrombin receptor antagonists. Br J Clin Pharmacol. 2011;72(4):658–71.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    Article  CAS  PubMed  Google Scholar 

  13. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.

    Article  CAS  PubMed  Google Scholar 

  14. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982–8.

    Article  PubMed  Google Scholar 

  15. Duerschmied D, Bode C. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism? Hamostaseologie. 2012;32(3):221–7.

    Article  CAS  PubMed  Google Scholar 

  16. Martorell L, Martinez-Gonzalez J, Rodrigues C, et al. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost. 2008;99(2):305–15.

    CAS  PubMed  Google Scholar 

  17. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010;74(4):597–607.

    Article  CAS  PubMed  Google Scholar 

  18. Morrow DA, Scirica BM, Fox KA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial. Am Heart J. 2009;158(3):335–41.e3.

    Article  CAS  PubMed  Google Scholar 

  19. Merck Sharp & Dohme Ltd. Zontivity 2 mg film-coated tablets: EU summary of product characteristics. 2015. http://www.ema.europa.eu/ema. Accessed 5 Mar 2015.

  20. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20–33.

    Article  CAS  PubMed  Google Scholar 

  21. Chackalamannil SDR, Asberom T, Doller D, et al. A highly efficient total synthesis of (+)-himbacine. J Am Chem Soc. 1996;118:9812–3.

    Article  CAS  Google Scholar 

  22. Doller DCS, Czarniecki M, McQuade R, et al. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg Med Chem Lett. 1999;9:901–6.

    Article  CAS  PubMed  Google Scholar 

  23. Kosoglou T, Reyderman L, Kasserra C, et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2012;68(3):291–300.

    Article  CAS  PubMed  Google Scholar 

  24. Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012;68(3):249–58.

    Article  CAS  PubMed  Google Scholar 

  25. Chackalamannil SDR, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51(11):3061–4.

    Article  CAS  PubMed  Google Scholar 

  26. Chintala M, Kurowski S, Zhai Y, et al. SCH 530348 is a novel oral antiplatelet agent selective for protease-activated receptor-1 (PAR-1) receptor subtype without partial agonist activity. FASEB J. 2009;23(Meeting Abstract Suppl):757.6.

    Google Scholar 

  27. Storey RF, Kotha J, Smyth SS, et al. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost. 2014;111(5):883–91.

    Article  CAS  PubMed  Google Scholar 

  28. Kosoglou T, Hunt TL, Xuan F, et al. Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: a randomized, placebo- and positive-controlled, parallel group trial. Clin Pharmacol Drug Dev. 2014;3(1):18–24.

    Article  CAS  Google Scholar 

  29. Merck & Co. Inc. Zontivity™ (vorapaxar) tablets 2.08 mg (equivalent to 2.5 mg vorapaxar sulfate), for oral use: US prescribing information. 2014. http://www.merck.com. Accessed 11 Aug 2014.

  30. Ghosal A, Lu X, Penner N, et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos. 2011;39(1):30–8.

    Article  CAS  PubMed  Google Scholar 

  31. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404–13.

    Article  CAS  PubMed  Google Scholar 

  32. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation. 2013;127(14):1522–9.

    Article  CAS  PubMed  Google Scholar 

  33. Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013;44(3):691–8.

    Article  CAS  PubMed  Google Scholar 

  34. Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012;380(9850):1317–24.

    Article  CAS  PubMed  Google Scholar 

  35. Magnani G, Bonaca MP, Braunwald E, et al. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015;4:e001505.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Cavender MA, Scirica BM, Bonaca MP, et al. Vorapaxar in patients with diabetes and prior MI: findings from the TRA 2°P-TIMI 50 trial. Circulation. 2015;131:1047–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Bohula May EA, Bonaca MP, Scirica BM, et al. Rates of arterial revascularization in patients treated with vorapaxar vs. placebo in the TRA 2°P-TIMI 50 trial. Circulation. 2012;126(21 Suppl 1):A19221.

    Google Scholar 

  38. Bonaca MP, Scirica BM, Braunwald E, et al. Efficacy of vorapaxar is not modified by thienopyridine therapy: results from TRA 2°P-TIMI 50 trial. Circulation. 2012;126(21 Suppl 1):A18595.

    Google Scholar 

  39. Bonaca MP, Scirica BM, Braunwald E, et al. Vorapaxar reduces coronary stent thrombosis: results from the TRA2P-TIMI 50 trial. Circulation. 2013;128(22 Suppl 1):A18928.

    Google Scholar 

  40. Food and Drug Administration. FDA draft briefing document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). Sponsor: Merck Sharp & Dohme Corp, Inc. Drug: Zontivity (vorapaxar sulfate) 2.5 mg tablets. 2014. http://www.fda.gov. Accessed 25 Mar 2015.

  41. Kalidas C. Vorapaxar in secondary prevention of atherothrombosis. http://www.fda.gov. Accessed 14 Oct 2014.

  42. Cardiovascular and Renal Drugs Advisory Committee Meeting. Vorapaxar advisory committee briefing document. Vorapaxar sulfate: secondary prevention of atherothrombosis in patients with a history of myocardial infarction. NDA 204886. 2014. http://www.fda.gov. Accessed 13 Oct 2014.

  43. European Medicines Agency. Zontivity. International non-proprietary name: vorapaxar. European public assessment report. 2015. http://www.ema.europa.eu. Accessed 25 Mar 2015.

  44. Wurster T, May AE. Atopaxar. A novel player in antiplatelet therapy? Hamostaseologie. 2012;32(3):228–33.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. James Frampton is a salaried employee of Adis/Springer.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay 0754, Auckland, New Zealand

    James E. Frampton

Authors
  1. James E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James E. Frampton.

Additional information

The manuscript was reviewed by: D. Duerschmied, Department of Cardiology and Angiology I Heart Center, University of Freiburg, Freiburg, Germany; M. Paciaroni, Stroke Unit and Division of Internal and Cardiovascular Medicine, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy; A Tello-Montoliu, Department of Cardiology, Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frampton, J.E. Vorapaxar: A Review of Its Use in the Long-Term Secondary Prevention of Atherothrombotic Events. Drugs 75, 797–808 (2015). https://doi.org/10.1007/s40265-015-0387-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-015-0387-9

Keywords

Search

Navigation